AnGes Inc

Overview

AnGes Inc (AnGes) is a biopharmaceutical company, which discovers and develops gene and nucleotide based drugs and reagents for use in the functional analysis of genetic medications. The company specializes in the research and development (R&D) and practical application of genetic medicines. It has two main projects under development, namely, a hepatocyte growth factor (HGF) plasmid, which is a genetic medicine that improves blood circulation by regenerating blood vessels and NF-KB decoy oligonucleotide. It also develops therapeutic vaccine projects including CIN (cervical intraepithelial neoplasia) therapeutic vaccines. The company has operations in Japan and the US. AnGes is headquartered in Osaka, Japan.
Key Stats
Address
7-7-15 Saito-asagi, Saito Bio-Incubator 4 Fl., IBARAKI-SHI, Osaka
Headquarters

Japan

Contact

81 3 57302641

Website
www.anges.co.jp
No of Employees

90

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

4563 [TYO]

Revenue (2020)

$0 m

-100% (2020 vs 2019)
Net Income (2020)

$-40 m

-15.9% (2020 vs 2019)
Net Profit Margin

-10524 %

-816.8% (2020 vs 2019)
Market Cap *

$1,084 m

EPS *

$-0.3

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters AnGes IncFuso Pharmaceutical Industries LtdTakara Bio IncKolon Life Science Inc
Key Information
Headquarters Japan Japan Japan South Korea
Headquarter City IBARAKI-SHI OSAKA-SHI KUSATSU-SHI SEOUL
Headquarter State/Province Osaka Osaka Shiga -
No. of Employees 90 1,356 1,539 439
Entity Type Public Public Public Public

Products & Services

AnGes specializes in the research and development and practical application of genetic medicine. The company's key products include the following:

Products
  • Pipeline:
  • HGF Plasmid (BeperminogenePerplasmid):
  • Chronic Arterial Occlusive Disease With Rest Pain
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Ei Yamada, Ph.D. President; Chief Executive Officer; Director Executive Board 2002 - Dr. Ei Yamada has been the President, Director and the Chief Executive Officer of the company since September 2002. Prior...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2020 Acquisitions/Mergers/Takeovers In December, the company acquired EmendoBio Inc., a biopharmaceutical company for US$250 million.
2020 Plans/Strategy In March, the company announced its plans to collaborate with Osaka University, to develop a…
2020 Contracts/Agreements In September, the company and Brickell Biotech entered into a collaboration to develop AnGes’ proprietary…
2019 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2019 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2019 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


EmendoBio Inc

Address

400 W 61st Street, New York
United States of America

Telephone

1 917 6755585

Website

emendobio.com
EmendoBio Inc

Address

400 W 61st Street, New York City
United States of America

Telephone

1 917 6755585

Website

emendobio.com

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
15 Dec 2020 AnGes Acquires EmendoBio Acquisition AnGes Inc EmendoBio Inc
15 Oct 2020 Er-Kim Enters into Licensing Agreement with AnGes Licensing Agreement Er-Kim Ilac Sanayi ve Ticaret AS AnGes Inc
08 Sep 2020 AnGes and Brickell Biotech Enter into Agreement to Develop Vaccine Candidate for COVID-19 Partnership AnGes Inc; Brickell Biotech Inc
05 Mar 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
15 Jan 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
12 Dec 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit